BACKGROUND: Attention deficit hyperactivity disorder is one of the neurodevelopmental disorders often seen in young people. The core symptoms include inattention, hyperactivity and impulsivity. .NICE guidelines recommend different treatments for ADHD and the first line pharmacological treatment advised is Methylphenidate. Regular monitoring of weight and height is advised by NICE guidelines for young people on Methylphenidate, as it may cause weight loss and growth retardation. The aim of this audit was to assess compliance with NICE guidelines regarding height and weight monitoring in young individuals attending a National Child and Adolescent Mental Health Community Clinic and receiving methylphenidate treatment.
Lia et al. (Wed,) studied this question.